pharmaceutical company executive
David Wayne Robertson was born on July 30, 1955, in Dumas, Texas, United States. He is the son of R.L. Robertson and Nixie Carolyn McDougal Robertson. He developed his professional career in pharmaceutical research, initially specializing in medicinal chemistry and subsequently moving into research management and executive leadership.
Robertson studied at Stephen F. Austin State University, where he earned a Bachelor of Science degree in 1977. He continued his graduate education at the University of Illinois, receiving a Master of Science degree in 1978 and a Doctor of Philosophy degree in 1981. His advanced scientific training provided the foundation for a career combining medicinal chemistry with pharmaceutical research and development.
Robertson began his pharmaceutical career in 1981 with Eli Lilly and Company in Indianapolis, Indiana, as a senior medicinal chemist. He subsequently served as a research scientist from 1985 to 1987 and as a senior research scientist from 1988 to 1989. During 1988-1989 he also served as a research group leader, taking on increasing responsibility for scientific research and drug-discovery activities.
His work at Eli Lilly included research involving compounds affecting the central nervous system and serotonin-related biological systems. Patent records identify Robertson as an inventor on a number of Eli Lilly inventions. Among them was a group of 3-aryloxy-3-substituted propanamines described for their ability to inhibit serotonin and norepinephrine uptake. He was also named as an inventor on work concerning fluoxetine analogs and other compounds affecting serotonin receptors.
In 1990-1991, Robertson became director of central nervous system research at Eli Lilly. This marked a transition from primarily laboratory-based medicinal chemistry into broader scientific and research leadership.
In 1991 he joined Ligand Pharmaceuticals in San Diego, California, as vice president of medicinal chemistry. He became vice president of research in 1992 and vice president of discovery research in 1993, a position he held through 1996. His progression at Ligand reflected an increasing focus on directing discovery programs and integrating medicinal chemistry with wider pharmaceutical research.
Robertson subsequently became executive director of research and development at DuPont Pharmaceutical Company. Later career information places him with Pharmacia & Upjohn as vice president of research from 1999 to 2001 and with Pfizer as executive director of global research and development in 2002. These positions extended his career from individual drug-discovery research into leadership of large-scale pharmaceutical R&D organizations.
His patent record also documents continuing involvement in pharmaceutical research during the Pharmacia & Upjohn period. A 2003 international patent filing concerning compounds for the treatment of addiction disorders lists David Wayne Robertson as an inventor and identifies Pharmacia & Upjohn Company as the applicant.
Robertson's scientific contributions include a substantial body of patented medicinal-chemistry work. Patent records associate him with inventions involving serotonin and norepinephrine uptake inhibitors, serotonin antagonists, guanidine derivatives, and other pharmaceutical compounds.
Robertson has been recognized as a pharmaceutical executive by Marquis Who's Who. His professional record combines laboratory research, medicinal chemistry, central nervous system drug discovery, and executive management of pharmaceutical research and development. He was named as an inventor on multiple international pharmaceutical patents, particularly during his years with Eli Lilly and later Pharmacia & Upjohn.
Robertson has been associated with the Society for Neuroscience, the American Society for Pharmacology and Experimental Therapeutics, and the American Chemical Society. His memberships reflect his scientific background in medicinal chemistry, pharmacology, neuroscience, and pharmaceutical research.
